CenterBook Partners LP Buys New Holdings in Abivax SA Sponsored ADR $ABVX

CenterBook Partners LP purchased a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 7,176 shares of the company’s stock, valued at approximately $968,000.

Several other institutional investors and hedge funds have also bought and sold shares of ABVX. TCG Crossover Management LLC boosted its holdings in shares of Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after acquiring an additional 1,055,000 shares during the last quarter. UBS Group AG raised its holdings in shares of Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in Abivax during the third quarter valued at $263,698,000. Paradigm Biocapital Advisors LP acquired a new position in Abivax during the third quarter valued at $132,800,000. Finally, Octagon Capital Advisors LP boosted its holdings in Abivax by 3.0% in the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after purchasing an additional 37,000 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Price Performance

Shares of NASDAQ:ABVX opened at $98.03 on Thursday. The business’s 50 day moving average price is $116.59 and its 200-day moving average price is $119.41. Abivax SA Sponsored ADR has a 1 year low of $5.69 and a 1 year high of $148.83. The firm has a market capitalization of $7.81 billion, a price-to-earnings ratio of -18.82 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts expect that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Truist Financial cut their price target on Abivax from $140.00 to $135.00 and set a “buy” rating on the stock in a research report on Tuesday, June 2nd. Morgan Stanley lowered their target price on Abivax from $145.00 to $132.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 2nd. Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Finally, Citigroup reissued an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $130.08.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.